• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Valeant's Shares Could Rebound if Papa Named New CEO, Analysts Say

Wall Street is confident that Valeant can turn around its steep share price decline with the right successor as CEO.
By JAMES PASSERI Apr 22, 2016 | 12:50 PM EDT
Stocks quotes in this article: VRX, PRGO

Valeant Pharmaceuticals' (VRX) shares jumped in midday trading Friday after reports surfaced that the beleaguered drugmaker has courted Joseph Papa, the CEO of Irish competitor Perrigo (PRGO), to replace Michael Pearson at the helm of Valeant.

And it appears investors have good reason to be bullish, some analysts say.

One reason the news should restore shareholder confidence is that Papa has overseen a roughly 900% share-price increase at Perrigo since he became CEO in 2006, and his ability to shrewdly make acquisitions will be a major benefit for Valeant, whose shares are down 65% this year alone, BMO Capital analyst Alex Arfaei said in a Friday investment note.

"Moreover, he has led Perrigo's through a number of acquisitions, including Elan in 2013, which was basically a tax inversion," Arfaei said. "Mr. Papa's focus on buying consumer and over-the-counter businesses (e.g., Omega, GSK OTC assets) is well aligned with Valeant's strategy and key business units." 

And the news comes just as Pearson, the departing CEO at Valeant, prepares to testify before the Senate Special Committee on Aging next week surrounded by allegations of dubious drug-pricing policies at Valeant. The charges have been most prominently highlighted by Democratic presidential candidate Hillary Clinton, who has said Valeant is "gouging" patients through "predatory pricing."

And chatter surrounding the appointment of Papa -- who also served as chief operating officer of DuPont (DD) in 2001 -- is also a potential catalyst for a Valeant turnaround because it may signal that much of Valeant's accounting woes are settled, and that "challenges are not insurmountable," analysts  with Morgan Stanley said in a Friday report.

"We view the news as positive for VRX shares; it is encouraging that a highly experienced CEO of an $18.4 billion market cap company appears interested in being CEO of $11.4 billion market cap Valeant," the analysts said.

Meanwhile, Bill Ackman -- the billionaire activist whose hedge fund, Pershing Square, maintains a 9% stake in Valeant --  appears to share the view that a new CEO is an essential next step for Valeant to begin staging a meaningful share-price reversal.

"We expect fairly rapid recovery of the stock price on the basis of restoring confidence in the business," Ackman said on Pershing Square investor call this month, emaphasizing "very interesting and good segments for a CEO to step in." (Ackman, along with Pershing's vice-chairman, Stephen Fraidin, also recently obtained seats on Valeant's board.)

Valeant shares have been in the doldrums this year largely because the drugmaker has scrambled to timely file its annual 10-K statement with the SEC amid Congressional and SEC probes into it's accounting and drug pricing practices.

The company has so far acknowledged about $58 million in improperly booked revenue tied to its former partnership with mail-order pharmacy Philidor. And while Valeant has said there are likely no more skeletons in the closet, and that it will file its 10-K on or before April 29, the drugmaker still risks entering a technical default if it is not able to reach consensus with creditors in ironing out breached covenants on its bonds and loans.

Most recently, after doling out a host of concessions to holders of its roughly $11 billion in loans, Valeant managed to push its 10-K filing deadline to May 31. But bondholders quickly reacted with the filing of a default notice less than a week later.

"Overall, if true, this should be positive news for VRX investors," Arfaei said in his note to investors. "We continue to believe that VRX could be on the verge of a significant inflection point; and we look forward to reviewing the company's 10-K, which we hope will be filed on time by April 29."

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login